Literature DB >> 9671025

Doxycycline-induced transgene expression during Drosophila development and aging.

E T Bieschke1, J C Wheeler, J Tower.   

Abstract

The "reverse" tetracycline repressor (rtR) binds a specific DNA element, the tetracycline operator (tetO), only in the presence of tetracycline, or derivatives such as doxycycline (dox). Fusion of rtR to the transcriptional activation domain of herpes virus protein VP16 produces a eukaryotic transactivator protein (rtTA). rtTA has previously been shown to allow dox-dependent transcription of transgenes linked to tetO sequences in mammals. To adapt this system to Drosophila, the Actin5C promoter was used to drive constitutive expression of rtTA in transgenic flies. Three reporter constructs, each encoding E. coli beta-galactosidase (beta-gal), were also introduced into transgenic flies. In one reporter seven tetO sequences were fused to the Adh core promoter. The other two reporter constructs contain seven tetO sequences fused to the hsp70 core promoter. Feeding of transgenic Drosophila containing the rtTA construct and any one of the three reporter constructs with dox caused up to 100-fold induction of beta-gal. Dox induced beta-gal expression in all tissues, in larvae and in young and senescent adults. Induction of beta-gal in adults had no detectable effect on life span. These results suggest the potential usefulness of this system for testing specific genes for effects on Drosophila development and aging.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671025     DOI: 10.1007/s004380050770

Source DB:  PubMed          Journal:  Mol Gen Genet        ISSN: 0026-8925


  31 in total

1.  A conditional tissue-specific transgene expression system using inducible GAL4.

Authors:  T Osterwalder; K S Yoon; B H White; H Keshishian
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

2.  Conditional switches for extracellular matrix patterning in Drosophila melanogaster.

Authors:  Arvinder Khokhar; Nan Chen; Ji-Ping Yuan; Yishi Li; Gary N Landis; Gregory Beaulieu; Harminder Kaur; John Tower
Journal:  Genetics       Date:  2008-02-03       Impact factor: 4.562

3.  Promoter-proximal pausing on the hsp70 promoter in Drosophila melanogaster depends on the upstream regulator.

Authors:  H Tang; Y Liu; L Madabusi; D S Gilmour
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

4.  High-frequency generation of conditional mutations affecting Drosophila melanogaster development and life span.

Authors:  G Landis; D Bhole; L Lu; J Tower
Journal:  Genetics       Date:  2001-07       Impact factor: 4.562

5.  The auxin-inducible degradation system enables conditional PERIOD protein depletion in the nervous system of Drosophila melanogaster.

Authors:  Wenfeng Chen; Michelle Werdann; Yong Zhang
Journal:  FEBS J       Date:  2018-10-25       Impact factor: 5.542

6.  Tetracycline-inducible systems for Drosophila.

Authors:  M J Stebbins; S Urlinger; G Byrne; B Bello; W Hillen; J C Yin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

7.  Spatial and temporal control of gene expression in Drosophila using the inducible GeneSwitch GAL4 system. I. Screen for larval nervous system drivers.

Authors:  Louise Nicholson; Gunisha K Singh; Thomas Osterwalder; Gregg W Roman; Ronald L Davis; Haig Keshishian
Journal:  Genetics       Date:  2008-01       Impact factor: 4.562

8.  Genetic approaches to study aging in Drosophila melanogaster.

Authors:  Luc Poirier; Laurent Seroude
Journal:  Age (Dordr)       Date:  2005-12-31

9.  FLP recombinase-mediated induction of Cu/Zn-superoxide dismutase transgene expression can extend the life span of adult Drosophila melanogaster flies.

Authors:  J Sun; J Tower
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

10.  Hydrogen peroxide stimulates activity and alters behavior in Drosophila melanogaster.

Authors:  Dhruv Grover; Daniel Ford; Christopher Brown; Nicholas Hoe; Aysen Erdem; Simon Tavaré; John Tower
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.